X

Drug Profile

TG 1000

Alternative Names: TG-1000

Latest Information Update: 24 Mar 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TaiGen Biotechnology
Class Antivirals
Mechanism of Action Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Influenza virus infections

Most Recent Events

22 Mar 2023 TG 1000 licensed to Joincare Pharmaceutical in China, Hong Kong and Macau
24 Aug 2022 TaiGen Biotechnology plans a meeting with Center for Drug Evaluation in China
24 Aug 2022 Efficacy and safety data from a phase II trial in Influenza virus infections released by TaiGen Biotechnology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com